Huaier improves the efficacy of anti-PD-L1 Ab in the treatment of hepatocellular carcinoma by regulating tumor immune microenvironment
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Huaier improves the efficacy of anti-PD-L1 Ab in the treatment of hepatocellular carcinoma by regulating tumor immune microenvironment
Authors
Keywords
-
Journal
PHYTOMEDICINE
Volume -, Issue -, Pages 155189
Publisher
Elsevier BV
Online
2023-11-05
DOI
10.1016/j.phymed.2023.155189
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Medicinal Mushroom Supplements in Cancer: A Systematic Review of Clinical Studies
- (2023) Santhosshi Narayanan et al. Current Oncology Reports
- Immunoregulatory effects of Huaier (Trametes robiniophila Murr) and relevant clinical applications
- (2023) Hongrong Long et al. Frontiers in Immunology
- Phase 3 randomized, open-label, multicenter study of tremelimumab (T) and durvalumab (D) as first-line therapy in patients (pts) with unresectable hepatocellular carcinoma (uHCC): HIMALAYA.
- (2022) Ghassan K. Abou-Alfa et al. JOURNAL OF CLINICAL ONCOLOGY
- A FAK Inhibitor Boosts Anti-PD1 Immunotherapy in a Hepatocellular Carcinoma Mouse Model
- (2022) Yuhua Wei et al. Frontiers in Pharmacology
- Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation
- (2022) Mengling Wu et al. Journal of Hematology & Oncology
- LBA35 Camrelizumab (C) plus rivoceranib (R) vs. sorafenib (S) as first-line therapy for unresectable hepatocellular carcinoma (uHCC): A randomized, phase III trial
- (2022) S. Qin et al. ANNALS OF ONCOLOGY
- LBA36 Final analysis of RATIONALE-301: Randomized, phase III study of tislelizumab versus sorafenib as first-line treatment for unresectable hepatocellular carcinoma
- (2022) S. Qin et al. ANNALS OF ONCOLOGY
- Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
- (2021) Hyuna Sung et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Angiogenesis, programmed death ligand 1 (PD-L1) and immune microenvironment association in laryngeal carcinoma
- (2021) Leonardo Franz et al. PATHOLOGY
- Anlotinib Induces a T Cell–Inflamed Tumor Microenvironment by Facilitating Vessel Normalization and Enhances the Efficacy of PD-1 Checkpoint Blockade in Neuroblastoma
- (2021) Yudong Su et al. CLINICAL CANCER RESEARCH
- PD−L1 immunostaining: what pathologists need to know
- (2021) Mohammed Akhtar et al. Diagnostic Pathology
- Huaier granule prevents the recurrence of early-stage hepatocellular carcinoma after thermal ablation: A cohort study
- (2021) Zhen Wang et al. JOURNAL OF ETHNOPHARMACOLOGY
- Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma
- (2021) Ann-Lii Cheng et al. JOURNAL OF HEPATOLOGY
- Camrelizumab in patients with previously treated advanced hepatocellular carcinoma: a multicentre, open-label, parallel-group, randomised, phase 2 trial
- (2020) Shukui Qin et al. LANCET ONCOLOGY
- Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib
- (2020) Thomas Yau et al. JAMA Oncology
- Small-Molecule MYC Inhibitors Suppress Tumor Growth and Enhance Immunotherapy
- (2019) Huiying Han et al. CANCER CELL
- Effect of Huaier granule on recurrence after curative resection of HCC: a multicentre, randomised clinical trial
- (2018) Qian Chen et al. GUT
- Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
- (2018) Andrew X Zhu et al. LANCET ONCOLOGY
- OA11.07 Combining Anti-Angiogenesis and Immunotherapy Enhances Antitumor Effect by Promoting Immune Response in Lung Cancer
- (2017) Sha Zhao et al. Journal of Thoracic Oncology
- Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial
- (2017) Anthony B El-Khoueiry et al. LANCET
- Huaier Restrains Proliferative and Migratory Potential of Hepatocellular Carcinoma Cells Partially Through Decreased Yes-Associated Protein 1
- (2017) Liang Shan et al. Journal of Cancer
- Combination immunotherapy: a road map
- (2017) Patrick A. Ott et al. Journal for ImmunoTherapy of Cancer
- Huaier aqueous extract sensitizes cells to rapamycin and cisplatin through activating mTOR signaling
- (2016) Zhongdong Hu et al. JOURNAL OF ETHNOPHARMACOLOGY
- Expansion of the Gene Ontology knowledgebase and resources
- (2016) NUCLEIC ACIDS RESEARCH
- A Huaier polysaccharide reduced metastasis of human hepatocellular carcinoma SMMC-7721 cells via modulating AUF-1 signaling pathway
- (2015) Cong Li et al. TUMOR BIOLOGY
- A polysaccharide from mushroom Huaier retards human hepatocellular carcinoma growth, angiogenesis, and metastasis in nude mice
- (2014) Yanmei Zou et al. TUMOR BIOLOGY
- A Huaier polysaccharide inhibits hepatocellular carcinoma growth and metastasis
- (2014) Cong Li et al. TUMOR BIOLOGY
- A polysaccharide from the fungi of Huaier exhibits anti-tumor potential and immunomodulatory effects
- (2012) Yi Sun et al. CARBOHYDRATE POLYMERS
- Anti-angiogenic and antitumor activities of Huaier aqueous extract
- (2012) XIAOLONG WANG et al. ONCOLOGY REPORTS
- Inhibitory effect of extract of fungi of Huaier on hepatocellular carcinoma cells
- (2010) Jianzhuang Ren et al. Journal of Huazhong University of Science and Technology-Medical Sciences
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started